Skip to main content
. 2020 Jan 20;80(2):147–165. doi: 10.1007/s40265-019-01245-3

Fig. 2.

Fig. 2

IDegLira initiation algorithm to provide guidance for physicians based on prior therapy of individuals with T2D. DPP-4i dipeptidyl peptidase 4 inhibitor, GLP-1RA glucagon-like peptide-1 receptor agonist, IDegLira insulin degludec/liraglutide, OAD oral antidiabetic drug, SU sulfonylurea

HHS Vulnerability Disclosure